Enhancing European Biotech Competitiveness Through Regulatory Reforms

The drive toward Enhancing European Biotech Competitiveness lies at the heart of the European Federation of Pharmaceutical Industries and Associations’ call to reinforce the European Commission’s Biotech Act proposal with wider intellectual property safeguards and quicker clinical research pathways.

This stance highlights that existing drafts, though broadly innovation-friendly, need wider incentive eligibility and stronger coordination to redirect capital toward Europe. Such steps are seen as vital for turning scientific excellence into commercial products and therapies reaching patients, further supporting Navigating Economic Resilience Through Life Sciences Investment across the continent.

Evidence from Stakeholder Consultations

The analysis stems from the formal consultation after the December 2025 proposal and earlier input collected from May to November 2025 that revealed shortcomings in the draft rules. EFPIA compares suggested changes to the Clinical Trials Regulation against global standards of roughly thirty-day reviews by competent authorities, checking whether joint multinational assessments and core dossier rules can shorten approval times without compromising safety or ethics.

Ad

Streamlining Incentives Across the Lifecycle

The twelve-month Supplementary Protection Certificate extension for certain biotechnology products and advanced therapies is welcomed as a starting point, yet its value depends on applying it to all innovative medicines rather than limiting it by technology type. Ideas such as regulatory sandboxes, aligned GDPR data reuse, and proportionate GMO exemptions are viewed as ways to cut red tape throughout development, with funding urged through scale-up stages to reduce relocation risks tied to long pharmaceutical timelines.

Retaining R&D Activity and Access

These proposals suggest that Biotech Act refinements could help Europe keep research activity by matching incentives to global supply realities. For health economics work, predictable pathways and coherent AI governance open chances to model faster patient access under streamlined trials, while market strategies must balance stronger European intellectual property signals with national value assessments to secure timely reimbursement and sustain Enhancing European Biotech Competitiveness, in line with the EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030. Broader evidence on Economic Impact of Industry Clinical Trials in Europe further underscores how these reforms could strengthen the region’s position.